Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (1250)	7/8/2002 9:45:32 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

Sorry, Harry. That was just a tad oblique. I don't follow Corixa. Many who do have gone "huh?" in response to FDA's constant abuse of the old Coulter project, the iodinated anti-CD20. But now FDA is going to air CRXA's dirty laundry, and let the molecule come in front of an advisory committee. We finally get to see why FDA never liked Coulter (now Corixa). I was trying to say..... physicians NEED a long acting atypical antipsychotic. Drug compliance helps to keep people off the street, where they can encounter exposure to cold, among other dangers. I was discussing this, in context of Peter's post....... biz.yahoo.com It's very weird, to say the least, to have a drug rejected and returned for PRECLINICAL testing. I was just saying that FDA should have a very strong, "no-brainer" case, and that, if they don't, JNJ should be in line with CRXA.